:format(webp))
With both autologous and allogeneic therapies requiring exact temperature controls and flawless coordination, traditional logistics frameworks are no longer sufficient to guarantee safety.
In this video, discover how QuickSTAT’s specialized CGT Service provides the robust infrastructure, end-to-end visibility, and meticulous handling required to safeguard advanced therapeutics. Learn how our customized logistics solutions are specifically designed to protect the integrity of your therapy at every crucial milestone from bench to bedside.
How QuickSTAT utilizes specialized cryogenic (Liquid Nitrogen/LN2), ultra-frozen, and controlled room temperature (CRT) shipping solutions to maintain strict thermal boundaries throughout transit.
The rigorous monitoring and tracking protocols implemented to manage highly personalized, patient-specific shipments, eliminating the risk of product mix-ups.
How our dedicated CGT control towers monitor flights, weather disruptions, and customs clearance procedures 24/7/365 to intervene before delays occur.
A look at QuickSTAT’s expanding network of GDP-compliant facilities designed to support advanced therapies from early-phase clinical trials to commercial launch.
Loading iFrame
Press play to get started.
In autologous CGT trials, a single patient is often both the source and the recipient of the medicine. A logistical failure doesn't just damage product—it can directly deny a patient their treatment window.
Living cells and genetic materials are highly fragile and often impossible to remanufacture or replace; ensuring absolute cold chain integrity is paramount.
Partnering with a specialized CGT expert ensures total alignment with global regulatory expectations, protecting your data integrity and trial validation.